Chantix Tagged Articles

New warnings added to Chantix label include cardiovascular events, psychiatric symptoms

Posted: March 20, 2013 Pharmaceutical

The safety label for the smoking cessation drug Chantix (varenicline) has been updated to include new warnings about cardiovascular risks. The warning is based on a large, combined analysis of clinical trials that showed more serious cardiovascular events occurred in

Analysis finds more serious cardiovascular events in people who use Chantix

Posted: December 17, 2012 Pharmaceutical

More serious cardiovascular events occurred in people who were taking the smoking cessation drug Chantix (varenicline) compared to people who were taking a placebo, according to a large, combined analysis of clinical trials on the effects of Chantix.

Anti-smoking drug Chantix may help other addicts, but at what cost?

Posted: February 20, 2012 Pharmaceutical

Two new clinical studies have found evidence that Pfizers’s anti-smoking drug Chantix (varenicline) may help take the enjoyment out of cocaine and alcohol in much the same way it makes smoking cigarettes feel less desirable, thereby easing addiction and making

UC doctor finds statin drugs may cause anger, hostility in rare cases

Posted: November 12, 2011 Pharmaceutical

Some people taking Pfizer’s smoking-cessation drug Chantix have reportedly experienced fits of hostility. Anti-depression medications and other drugs that work to modify brain activity have also been linked to episodes of violent behavior. But what about statins, the drugs commonly

Chantix risks are far greater than other stop-smoking drugs, new study finds

Posted: November 3, 2011 Product Liability

The authors of a study published Wednesday in the science and medical journal PLoS One say that Pfizer’s smoking cessation drug Chantix “shows a substantial, statistically significant increased risk of reported depression and suicidal/self-injurious behavior” than other smoking cessation drugs

Chantix significantly increases cardiovascular risks, according to another new study

Posted: July 8, 2011 Pharmaceutical

Last month, the Food and Drug Administration warned of newly discovered cardiovascular risks associated with Pfizer’s popular smoking-cessation drug Chantix. But it turns out those risks, which include higher occurrence of heart attack and other adverse cardiovascular events in Chantix

FDA warns of new heart risks associated with Chantix

Posted: June 20, 2011 Pharmaceutical

For many smokers trying to kick their addiction, the latest news about the dangers of Pfizer’s smoking-cessation drug Chantix presents as a damned if you do, damned if you don’t dilemma. The U.S. Food and Drug Administration issued an alert

Chantix suicides and violence much more common, newly found reports show

Posted: May 31, 2011 Pharmaceutical

A senior scientist working for the non-profit Institute for Safe Medicine Practices has discovered that Chantix is a much more dangerous drug than has been officially acknowledged after finding hundreds of serious adverse reactions were reported to the FDA by

New warnings for off-label smoking addiction drug Aplenzin

Posted: May 23, 2011 Product Liability

The antidepressant Aplenzin (bupropion hydrobromide) extended-release tablets has a new black box warning against the use of the drug to help people quit smoking. The drug is approved by the Food and Drug Administration (FDA) only for the treatment of

Health Canada issues stronger warnings about Champix,Chantix

Posted: June 9, 2010 Pharmaceutical

Health Canada has ordered Pfizer Canada to issue stronger warnings about its smoking cessation medication Champix, also known as Chantix in the United States, because of numerous reports of serious neuropsychiatric symptoms and some cases of the potentially fatal skin